Article
Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer.
Future oncology (London, England) - 1 Apr 2017
Vincent Mark D, Breadner Daniel, Soulieres Denis, Kerr Ian G, Sanatani Michael, Kocha Walter, Klimo Peter, MacKenzie Mary J, O'Connell Anne, Whiston Frances, Malpage Anne S, Stitt Larry, Welch Stephen A
Abstract excerpt
Aim & methods: Capecitabine monotherapy as palliation for advanced colorectal cancer (CRC) is generally well tolerated. Adding erlotinib, an EGFR-tyrosine kinase inhibitor, might improve efficacy versus capecitabine alone. 82 patients received capecitabine alone (Arm 1) or capecitabine with erlotinib (Arm 2). RESULTS: Median time-to-progression (TTP) in Arm 1 was 7.9 months versus 9.2 in Arm 2. In KRAS-wild type...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.